Literature DB >> 2137984

Direct effects of endothelin in the rat kidney.

T Katoh1, H Chang, S Uchida, T Okuda, K Kurokawa.   

Abstract

In the present study, we tested the direct effects of endothelin (ET) on rat kidney in vivo. ET was infused into the left renal artery of anesthetized rats at a rate of 0.5, 5, 20, or 40 pmol/h. ET reduced ipsilateral urine volume (V), clearance of inulin (CIN), and clearance of p-aminohippuric acid (CPAH) in a dose-dependent manner. Thus ET at 20 pmol/h did not change V but decreased renal plasma flow (RPF) and glomerular filtration rate (GFR) by 27.6 +/- 14.3 and 30.8 +/- 10.4%, respectively, in the ipsilateral kidney. ET at 0.5 pmol/h was without effect and at 5 pmol/h had only minor effects on CIN and CPAH of ipsilateral kidney. At 40 pmol/h, ET reduced ipsilateral V, GFR, and RPF by 52.3 +/- 21.4, 58.4 +/- 14.5, and 72.5 +/- 10.6%, respectively. Filtration fraction and fractional excretion of Na remained unchanged during ET infusion. ET, 40 pmol/h, infused into the renal artery together with atrial natriuretic peptide (ANP) at a rate of 12 pmol/h reduced the ipsilateral V, GFR, and RPF by 33.2 +/- 6.3, 26.1 +/- 6.0, and 27.2 +/- 7.1%, respectively, decrements less than those with ET alone. When a calcium-channel blocker nicardipine was infused at a rate of 2.5 micrograms/h into the renal artery together with ET, 20 pmol/h, there was little change in the ipsilateral V, RPF, and GFR; ET, 40 pmol/h, with nicardipine did not change V and decreased GFR and RPF by 25.9 +/- 5.6 and 23.1 +/- 10.8%, respectively, decrements less than those without nicardipine.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137984     DOI: 10.1152/ajprenal.1990.258.2.F397

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 2.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 3.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 4.  Response of substances co-expressed in hypothalamic magnocellular neurons to osmotic challenges in normal and Brattleboro rats.

Authors:  Jana Bundzikova; Zdeno Pirnik; Dora Zelena; Jens D Mikkelsen; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2008-09-05       Impact factor: 5.046

Review 5.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 6.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Nitric oxide modulates renal vasoconstrictor effect of endothelin-1 in conscious lambs.

Authors:  Francine G Smith; Liesbeth van der Velde; Alp Sener
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

8.  Role of endogenous endothelin in renal haemodynamics of newborn rabbits.

Authors:  D S Semama; M Thonney; J P Guignard
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

9.  Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock.

Authors:  E Weitzberg; A Hemsén; A Rudehill; A Modin; M Wanecek; J M Lundberg
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

10.  Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression.

Authors:  J D Firth; P J Ratcliffe
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.